Menu
Svensk version

BONESUPPORT™ - Q2 2017 Interim Report – invitation to conference call and webcast

Lund, Sweden, 11 August 2017– BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery, will publish its Q2 2017 Interim Report on Thursday 17 August 2017 at 08:00 CEST.

 

The Company will also host a conference call and an online presentation on the same day at 10am CEST.

 

The dial-in numbers for the conference call are:

UK: +44 20 30089802

SE: +46 85 6642694

US: +1 855 8315948

 

The presentation will also be webcast and can be accessed from the following web address: http://www.financialhearings.com/event/10390

 

Hosts: Richard Davies, CEO, and Björn Westberg, CFO

 

 

Notes to Editor

About BONESUPPORT

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bioceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT’s marketed synthetic bone graft substitutes CERAMENT™ BONE VOID FILLER (BVF), CERAMENT™ G* and CERAMENT™ V* are all based on the Company’s novel and proprietary CERAMENT technology platform.

 

The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot. The Company’s research and development is focused on the continuing development and refinement of its existing technology to extend its use into additional indications by the elution of other drugs and therapeutic agents.

 

BONESUPPORT’s products are based on an innovative technology backed by an intellectual property portfolio of approximately 100 registered and/or pending patents. BONESUPPORT has a nine year track record of safety and efficacy in treating patients with an estimated number of 30,000 procedures performed to date with its products worldwide based on sales data.

 

BONESUPPORT’s total sales increased from SEK 41 million in 2014 to SEK 105 million in 2016, representing a compound annual growth rate of 60 percent.

 

The Company’s financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.

BONESUPPORT was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT’s mission is to bring people with bone and joint diseases back to an active life. The Company is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com

*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States

BONESUPPORT™ is a registered trademark.

 

Contact Information

BONESUPPORT AB

Richard Davies, CEO

Tel: +46 (0) 46 286 53 70

 

Björn Westberg, CFO

Tel: +46 (0) 46 286 53 60

Email: ir@bonesupport.com  

 

Citigate Dewe Rogerson

David Dible, Pip Batty, Marine Perrier

+44 (0)20 7638 9571

bonesupport@citigatedr.co.uk

 

Downloads

Press release PDF (593 KB)

BONESUPPORT, Mon Aug 7, 2017

BONESUPPORT is a #medtech company dedicated to development of injectable osteoconductive biomaterials https://t.co/SZVyGV3pkq

BONESUPPORT, Fri Aug 4, 2017

BONESUPPORT is a Scandinavian #medtech company dedicated to development of injectable osteoconductive biomaterials, https://t.co/SZVyGULOsS

BONESUPPORT, Tue Jul 4, 2017

BONESUPPORT is a Scandinavian #medtech company dedicated to development of injectable osteoconductive biomaterials, https://t.co/SZVyGULOsS